Literature DB >> 22423135

Septic shock attributed to Candida infection: importance of empiric therapy and source control.

Marin Kollef1, Scott Micek, Nicholas Hampton, Joshua A Doherty, Anand Kumar.   

Abstract

BACKGROUND: Delayed treatment of candidemia has previously been shown to be an important determinant of patient outcome. However, septic shock attributed to Candida infection and its determinants of outcome have not been previously evaluated in a large patient population.
METHODS: A retrospective cohort study of hospitalized patients with septic shock and blood cultures positive for Candida species was conducted at Barnes-Jewish Hospital, a 1250-bed urban teaching hospital (January 2002-December 2010).
RESULTS: Two hundred twenty-four consecutive patients with septic shock and a positive blood culture for Candida species were identified. Death during hospitalization occurred among 155 (63.5%) patients. The hospital mortality rate for patients having adequate source control and antifungal therapy administered within 24 hours of the onset of shock was 52.8% (n = 142), compared to a mortality rate of 97.6% (n = 82) in patients who did not have these goals attained (P < .001). Multivariate logistic regression analysis demonstrated that delayed antifungal treatment (adjusted odds ratio [AOR], 33.75; 95% confidence interval [CI], 9.65-118.04; P = .005) and failure to achieve timely source control (AOR, 77.40; 95% CI, 21.52-278.38; P = .001) were independently associated with a greater risk of hospital mortality.
CONCLUSIONS: The risk of death is exceptionally high among patients with septic shock attributed to Candida infection. Efforts aimed at timely source control and antifungal treatment are likely to be associated with improved clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22423135     DOI: 10.1093/cid/cis305

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  136 in total

1.  [Treatment of invasive mycoses. What can be done when therapy fails?].

Authors:  F Bloos
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

2.  Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels.

Authors:  S Kurland; M Furebring; E Löwdin; E Eliasson; E I Nielsen; J Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

Review 3.  Essentials in Candida bloodstream infection.

Authors:  Sibylle C Mellinghoff; O A Cornely; N Jung
Journal:  Infection       Date:  2018-09-14       Impact factor: 3.553

4.  Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.

Authors:  Elodie Gautier-Veyret; Xavier Fonrose; Julia Tonini; Anne Thiebaut-Bertrand; Mireille Bartoli; Jean-Louis Quesada; Claude-Eric Bulabois; Jean-Yves Cahn; Françoise Stanke-Labesque
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

5.  Discrimination of Candida albicans from Candida dubliniensis by Use of the BioFire FilmArray Blood Culture Identification Panel.

Authors:  Timothy R Southern; Aqilah Alelew; Peter C Iwen
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

Review 6.  Treatment principles for Candida and Cryptococcus.

Authors:  Laura C Whitney; Tihana Bicanic
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

Review 7.  Management of invasive candidiasis in nonneutropenic ICU patients.

Authors:  Emmanuel Weiss; Jean-François Timsit
Journal:  Ther Adv Infect Dis       Date:  2014-10

8.  The EMPIRICUS trial-the final nail in the coffin of empirical antifungal therapy in the intensive care unit?

Authors:  Michael Osthoff; Nina Khanna; Martin Siegemund
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

9.  Impact of Loading Dose of Caspofungin in Pharmacokinetic-Pharmacodynamic Target Attainment for Severe Candidiasis Infections in Patients in Intensive Care Units: the CASPOLOAD Study.

Authors:  Sébastien Bailly; Elodie Gautier-Veyret; Minh P Lê; Lila Bouadma; Olivier Andremont; Mathilde Neuville; Bruno Mourvillier; Romain Sonneville; Eric Magalhaes; Jordane Lebut; Aguila Radjou; Roland Smonig; Michel Wolff; Laurent Massias; Claire Dupuis; Jean-François Timsit
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

10.  A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality.

Authors:  Matteo Bassetti; Elda Righi; Filippo Ansaldi; Maria Merelli; Cecilia Trucchi; Trucchi Cecilia; Gennaro De Pascale; Ana Diaz-Martin; Roberto Luzzati; Chiara Rosin; Leonel Lagunes; Enrico Maria Trecarichi; Maurizio Sanguinetti; Brunella Posteraro; Jose Garnacho-Montero; Assunta Sartor; Jordi Rello; Giorgio Della Rocca; Massimo Antonelli; Mario Tumbarello
Journal:  Intensive Care Med       Date:  2014-05-08       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.